Advertisement

Topics

AdvanDx, Inc Company Profile

02:07 EDT 24th October 2017 | BioPortfolio

AdvanDx announces that at the recent American Society for Microbiology (ASM) meeting in Orlando, Florida, EVIGENE™ kits for detecting specific antibiotic resistance, virulence, and toxicity markers such as methicillin-resistance, vancomycin-resistance, PVL and TSST-1 in Staphylococcus aureus and enterococci, were launched for research use only in the United States. EVIGENE was officially launched for clinical use in Europe in April, 2006 at the 16th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) conference in Nice, France. EVIGENETM kits can be used for epidemiological purposes and help guide infection control measures to prevent serious infections with antibiotic resistant bacteria such as MRSA (Methicillin-resistant S. aureus), VRE (Vancomycin-resistant enterococci) and VRSA (Vancomycin-resistant S. aureus). The tools will also help US researchers develop the means by which to combat the high-profile, community-acquired MRSA (CA-MRSA) “superbug” (link to USA Today article) that is causing serious infections in otherwise healthy adults and children (See PVL EVIGENE below). Increasing antibiotic use, especially the widespread overuse of methicillin and vancomycin, has led to the evolution of antibiotic resistant bacteria such as MRSA, VRE and VRSA that are more virulent and cause more severe infections. This has led the CDC to issue specific warnings about the problem (Click here to see CDC warning) and is forcing hospital infection control and physicians to better understand the infectious bacteria they encounter and develop new strategies for combating them.

Location

10A Roessler Road
Woburn
Massachusetts
01801
United States of America

Contact

Phone: 1 781 376 0009
Fax: 1 781 376 0111
Email: info@AdvanDx.com


News Articles [1 Associated News Articles listed on BioPortfolio]

AdvanDx Inc Medical Equipment Deals and Alliances Profile [Report Updated: 11072017] Prices from USD $250

SummaryAdvanDx Inc AdvanDx, a subsidiary of OpGen Inc is a healthcare solution provider that offers rapid and accurate molecular diagnostic tests for identification of pathogens causing critical infec...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

AdvanDx, Inc.

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. Our mission...

AdvanDx

AdvanDx, Inc

AdvanDx announces that at the recent American Society for Microbiology (ASM) meeting in Orlando, Florida, EVIGENE™ kits for detecting specific antibiotic resistance, virulence, and toxicity markers ...

More Information about "AdvanDx, Inc" on BioPortfolio

We have published hundreds of AdvanDx, Inc news stories on BioPortfolio along with dozens of AdvanDx, Inc Clinical Trials and PubMed Articles about AdvanDx, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AdvanDx, Inc Companies in our database. You can also find out about relevant AdvanDx, Inc Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16  account for 96% of MRSA blood...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record